TACSTD2 and ovarian carcinoma: Trop-2-specific antitumor activity of Hu2G10 in preclinical models was shown in prostate cancer (DU-145), colon cancer (HT29, KM12SM, HCT-116 U5.5), ovarian cancer (SKOV-3), pancreatic cancer (BxPc3), breast cancer (SKBr3), but not in Trop-2-nil tumor models (Guerra et al., 2023a).